Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
企業コードTTNP
会社名Titan Pharmaceuticals Inc
上場日Jan 18, 1996
最高経営責任者「CEO」Mr. Weei Jye Chay
従業員数- -
証券種類Ordinary Share
決算期末Jan 18
本社所在地Suite 505
都市SAN FRANCISCO
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号94080
電話番号14152444990
ウェブサイトhttps://www.titanpharm.com/
企業コードTTNP
上場日Jan 18, 1996
最高経営責任者「CEO」Mr. Weei Jye Chay
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし